Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma Journal Article


Authors: Eguchi, T.; Kadota, K.; Chaft, J.; Evans, B.; Kidd, J.; Tan, K. S.; Dycoco, J.; Kolquist, K.; Davis, T.; Hamilton, S. A.; Yager, K.; Jones, J. T.; Travis, W. D.; Jones, D. R.; Hartman, A. R.; Adusumilli, P. S.
Article Title: Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma
Abstract: Purpose: The goals of our study were (a) to validate a molecular expression signature (cell cycle progression [CCP] score and molecular prognostic score [mPS; combination of CCP and pathological stage {IA or IB}]) that identifies stage I lung adenocarcinoma (ADC) patients with a higher risk of cancer-specific death following curative-intent surgical resection, and (b) to determine whether mPS stratifies prognosis within stage I lung ADC histological subtypes. Methods: Formalin-fixed, paraffin-embedded stage I lung ADC tumor samples from 1200 patients were analyzed for 31 proliferation genes by quantitative RT-PCR. Prognostic discrimination of CCP score and mPS was assessed by Cox proportional hazards regression, using 5-year lung cancer-specific mortality as the primary outcome. Results: In multivariable analysis, CCP score was a prognostic marker for 5-year lung cancer-specific mortality (HR=1.6 per interquartile range; 95% CI, 1.14-2.24; P=0.006). In a multivariable model that included mPS instead of CCP, mPS was a significant prognostic marker for 5-year lung cancer-specific mortality (HR=1.77; 95% CI, 1.18-2.66; P=0.006). Five-year lung cancer-specific survival differed between low-risk and high-risk mPS groups (96% vs 81%; P < 0.001). In patients with intermediate-grade lung ADC of acinar and papillary subtypes, high mPS was associated with worse 5-year lung cancer-specific survival (P < 0.001 and 0.015, respectively), compared with low mPS. Conclusion: This study validates CCP score and mPS as independent prognostic markers for lung cancer-specific mortality and provides quantitative risk assessment, independent of known high-risk features, for stage I lung ADC patients treated with surgery alone.
Keywords: overall survival; adjuvant therapy; chemotherapy; ccp score; molecular prognostic score
Journal Title: Oncotarget
Volume: 7
Issue: 23
ISSN: 1949-2553
Publisher: Impact Journals  
Date Published: 2016-06-07
Start Page: 35241
End Page: 35256
Language: English
DOI: 10.18632/oncotarget.9129
PROVIDER: scopus
PUBMED: 27153551
PMCID: PMC5085225
DOI/URL:
Notes: Article -- Export Date: 1 July 2016 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Jamie Erin Chaft
    166 Chaft
  2. William D Travis
    610 Travis
  3. Joseph Dycoco
    25 Dycoco
  4. Kyuichi Kadota
    84 Kadota
  5. David Randolph Jones
    205 Jones
  6. Takashi   Eguchi
    71 Eguchi
  7. Kay See   Tan
    116 Tan